Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial.

Verspyck E, Marpeau L, Lucas C

European journal of obstetrics, gynecology, and reproductive biology1 Mar 2000Cited by 22 (Europe PMC)

PMID10733017DOI10.1016/s0301-2115(99)00168-2PepBankPUB-10733017

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with uterine myomas, leuprorelin reduced myoma diameter by 26.5+/-4.5% versus 7.3+/-5% with lynestrenol (P=0.02).
In plain wordsIn women with uterine myomas, leuprorelin reduced myoma diameter more than lynestrenol.
Peptide
Leuprolide
Outcome
DecreaseMyoma diameter reduction
Study
n = 46
Comparator
Lynestrenol
Analysis
Primary
Outcome group
Tumor growth · Reproductive and sexual health
Studied dose
3.75 mg monthly · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Mean decrease in myoma diameter
26.5%
leuprorelin, +/- 4.5, n=29
Mean decrease in myoma diameter
7.3%
lynestrenol, +/- 5, n=17
Source sentences
Summary
Intent-to-treat analysis of the main efficacy criterion, namely ultrasonographic reduction of myoma(s) diameter, showed a significant difference in favour of leuprorelin (P=0.02) with a mean decrease of 26.5+/-4.5% (n=29) as opposed to 7.3+/-5% in the lynestrenol group (n=17).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-six women were randomly selected to receive, during 16 weeks, either monthly subcutaneous injections of leuprorelin 3.75 mg sustained release (n=33) or lynestrenol 5 mg two tabs per day (5th to the 25th menstrual cycle) (n=23).
Report a problemFND-1073301701
02HumanRandomized controlled trialEfficacy outcome
In women with uterine myomas, postoperative hematocrit decreased less with leuprorelin than lynestrenol (P=0.02).
In plain wordsIn women with uterine myomas, hematocrit decreased less after surgery with leuprorelin than lynestrenol.
Peptide
Leuprolide
Outcome
DecreasePostoperative hematocrit decrease
Study
n = 56
Comparator
Lynestrenol
Outcome group
Bleeding and clotting · Reproductive and sexual health
Studied dose
3.75 mg monthly · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Hematocrit decrease between the preoperative value and the value measured 48 h postoperatively was significantly lower in the leuprorelin group than in the lynestrenol one (P=0.02) (for hemoglobin: P=0.07).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-six women were randomly selected to receive, during 16 weeks, either monthly subcutaneous injections of leuprorelin 3.75 mg sustained release (n=33) or lynestrenol 5 mg two tabs per day (5th to the 25th menstrual cycle) (n=23).
Report a problemFND-1073301703
03HumanRandomized controlled trialEfficacy outcome
In women with uterine myomas, the difference in postoperative hemoglobin decrease between leuprorelin and lynestrenol was not significant (P=0.07).
In plain wordsIn women with uterine myomas, the hemoglobin difference between leuprorelin and lynestrenol after surgery was not statistically significant (P=0.07).
Peptide
Leuprolide
Outcome
No significant changePostoperative hemoglobin decrease
Study
n = 56
Comparator
Lynestrenol
Outcome group
Bleeding and clotting · Reproductive and sexual health
Studied dose
3.75 mg monthly · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Hematocrit decrease between the preoperative value and the value measured 48 h postoperatively was significantly lower in the leuprorelin group than in the lynestrenol one (P=0.02) (for hemoglobin: P=0.07).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-six women were randomly selected to receive, during 16 weeks, either monthly subcutaneous injections of leuprorelin 3.75 mg sustained release (n=33) or lynestrenol 5 mg two tabs per day (5th to the 25th menstrual cycle) (n=23).
Report a problemFND-1073301704
04HumanNon-randomized trialEfficacy outcome
In women with uterine myomas, clinical improvement was satisfactory with both leuprorelin and lynestrenol.
In plain wordsIn women with uterine myomas, both leuprorelin and lynestrenol produced satisfactory clinical improvement.
Peptide
Leuprolide
Outcome
Not applicableClinical improvement
Study
n = 33
Outcome group
Symptom improvement · Reproductive and sexual health
Studied dose
3.75 mg monthly · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Clinical improvement was satisfactory in both groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-six women were randomly selected to receive, during 16 weeks, either monthly subcutaneous injections of leuprorelin 3.75 mg sustained release (n=33) or lynestrenol 5 mg two tabs per day (5th to the 25th menstrual cycle) (n=23).
Report a problemFND-1073301702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.